In silico clinical trials for pediatric orphan diseases

被引:0
|
作者
A. Carlier
A. Vasilevich
M. Marechal
J. de Boer
L. Geris
机构
[1] Biomechanics Section,
[2] KU Leuven,undefined
[3] Celestijnenlaan 300C,undefined
[4] PB 2419,undefined
[5] 3000 Leuven,undefined
[6] Belgium and Biomechanics Research Unit,undefined
[7] University of Liège,undefined
[8] Chemin des Chevreuils 1 – BAT 52/3,undefined
[9] Prometheus,undefined
[10] Division of Skeletal Tissue Engineering,undefined
[11] KU Leuven,undefined
[12] O&N 1,undefined
[13] Herestraat 49,undefined
[14] PB 813,undefined
[15] MERLN Institute for Technology-Inspired Regenerative Medicine,undefined
[16] Maastricht University,undefined
[17] Universiteitssingel 40,undefined
[18] Skeletal Biology and Engineering Research Center,undefined
[19] KU Leuven,undefined
[20] O&N 1,undefined
[21] Herestraat 49,undefined
[22] PB 813,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
To date poor treatment options are available for patients with congenital pseudarthrosis of the tibia (CPT), a pediatric orphan disease. In this study we have performed an in silico clinical trial on 200 virtual subjects, generated from a previously established model of murine bone regeneration, to tackle the challenges associated with the small, pediatric patient population. Each virtual subject was simulated to receive no treatment and bone morphogenetic protein (BMP) treatment. We have shown that the degree of severity of CPT is significantly reduced with BMP treatment, although the effect is highly subject-specific. Using machine learning techniques we were also able to stratify the virtual subject population in adverse responders, non-responders, responders and asymptomatic. In summary, this study shows the potential of in silico medicine technologies as well as their implications for other orphan diseases.
引用
收藏
相关论文
共 50 条
  • [1] In silico clinical trials for pediatric orphan diseases
    Carlier, A.
    Vasilevich, A.
    Marechal, M.
    de Boer, J.
    Geris, L.
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [2] Clinical trials in pediatric neurologic diseases
    Ferriero, DM
    [J]. CURRENT OPINION IN PEDIATRICS, 2002, 14 (06) : 663 - 663
  • [3] Clinical trials of orphan medicines
    Buckley, Brendan M.
    [J]. LANCET, 2008, 371 (9629): : 2051 - 2055
  • [4] Improving the status of clinical trials in pediatric gastrointestinal diseases
    Oliva-Hemker, M
    Schwarz, KB
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2002, 35 (04): : 468 - 469
  • [5] Translational approaches to treating dynamical diseases through in silico clinical trials
    Alfonso, Sofia
    Jenner, Adrianne L.
    Craig, Morgan
    [J]. CHAOS, 2020, 30 (12)
  • [6] Clinical Trials of Orphan Drugs for Cancer
    Saltonstall, Peter L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (14): : 1545 - 1545
  • [7] Orphan pediatric diseases: regarding the world rare diseases day
    Gonzales de la Vega, Luis
    Hernandez-Cordova, Gustavo
    Solorzano, Sendy
    [J]. REVISTA MEDICA DE CHILE, 2013, 141 (02) : 270 - 271
  • [8] PEDIATRIC CLINICAL PHARMACOLOGY AND THERAPEUTIC ORPHAN
    DONE, AK
    COHEN, SN
    STREBEL, L
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1977, 17 : 561 - 573
  • [9] Regulatory Considerations for Developing Drugs for Rare Diseases: Orphan Designations and Early Phase Clinical Trials
    Pariser, Anne R.
    Xu, Kui
    Milto, John
    Cote, Timothy R.
    [J]. DISCOVERY MEDICINE, 2011, 11 (59) : 367 - 375
  • [10] Orphandev, French Clinical Trials Network dedicated to Orphan drugs and therapeutics development for rare diseases
    Yolande Adjibi
    Joëlle Micallef
    Olivier Blin
    [J]. Orphanet Journal of Rare Diseases, 5 (Suppl 1)